An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy — AV-X-02  

Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen Clinical Trial

Official title: An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy

Status Completed

Clinical Trial Summary

This trial is an open, national, multi-centre trial. The trial will be initiated in December 2013 and subjects will receive treatment for 6 weeks.

Safety monitoring will be performed in an ongoing basis through a Clinical Safety Group with immediate access to Adverse Events registered in the clinical database. The composition, procedures and deliverables of the Clinical Safety Group will be detailed in a Safety Agreement prior to trial start.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen
• Conjunctivitis, Allergic

• NCT number: NCT02065856
• Study type: Interventional
• Source: ALK-Abelló A/S
• Status: Completed
• Phase: Phase 2
• Start date: December 2013
• Completion date: December 2014